S-1,2,3,4-四氢异喹啉-3-羧酸苄酯盐酸盐 | 77497-96-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: S-1,2,3,4-四氢异喹啉-3-羧酸苄酯盐酸盐
• 中文别名: (S)-1,2,3,4-四氢异喹啉-3-羧酸苄酯
• 英文名称: benzyl (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate
• 英文别名: benzyl (3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate；(S)-Benzyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate
• CAS: 77497-96-2
• 化学式: C₁₇H₁₇NO₂
• 分子量: 267.327
• InChiKey: CAKWIRNQEKMHOR-INIZCTEOSA-N

物化性质

• 沸点：
  411.6±33.0 °C(Predicted)
• 密度：
  1.159
• 溶解度：
  二甲基亚砜、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  S-1,2,3,4-四氢异喹啉-3-羧酸苄酯盐酸盐 在 palladium on activated charcoal N-甲基吗啉 、 氢气 、 叔丁基锂 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 以 四氢呋喃 、 正戊烷 为溶剂， 反应 72.0h， 生成 (1R,3S)-1-(m-benzyloxybenzyl)-2-pivaloyl-Tic-(S)-Phe-OBn
  参考文献：
  名称：

  合成 1-(m-Hydroxybenzyl)-取代的 1,2,3,4-四氢异喹啉-3-羧酸衍生物作为阿片肽模拟物——温和条件下意外的酰胺键断裂

  摘要：

  N-Glycyl-(1R,3S)-1-(m-hydroxybenzyl)-1,2,3,4-四氢异喹啉-3-羧酸 (Tic) 被制备为 Tyr-Tic 二肽模拟物，以探索其作为δ阿片受体选择性配体。该化合物是通过从 L-Tic 开始的立体选择性合成成功获得的。在反应过程中，在温和条件下观察到了不寻常的肽键断裂，并提出了反应机制。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003)

  DOI：

  10.1002/ejoc.200300175
• 作为产物：
  描述：

  (S)-(-)-1,2,3,4-四氢-3-异喹啉羧酸苄酯 对甲苯磺酸盐 在 碳酸氢钠 作用下， 以 乙酸乙酯 为溶剂， 生成 S-1,2,3,4-四氢异喹啉-3-羧酸苄酯盐酸盐
  参考文献：
  名称：

  Facile Preparation of optically Pure (3S)- and (3R)- 1, 2, 3, 4-Tetrahydroisoquinoline-3-carboxylic Acid

  摘要：

  光学纯的(3S)-1, 2, 3, 4-四氢异喹啉-3-羧酸(1)通过对其苄基酯(2b)的分馏结晶法轻松获得，该苄基酯是由部分消旋的1盐酸盐制备而成，随后经过催化去苄基化。同样，(3R)-1也是通过相同的程序制备的。在使用光学活性的苯丙氨酸进行Pictet-Spengler反应时，通过在存在手性位移试剂的情况下，对反应产物(1)所得到的相应甲基酯(2a)进行1H核磁共振(1H-NMR)光谱分析，确定了消旋化的程度。

  DOI：

  10.1248/cpb.31.312

文献信息

• [EN] CRYSTALLINE FORM OF QUINAPRIL HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME<br/>[FR] FORME CRISTALLINE D'UN HYDROCHLORURE DE QUINAPRIL ET PROCEDE DE PREPARATION DE CELLE-CI
  申请人：LUPIN LTD

  公开号：WO2004054980A1

  公开（公告）日：2004-07-01

  A novel crystalline form of quinapril hydrochloride of formula (I). An amorphous form of quinapril hydrochloride substantially free of impurities, specially diketopiperazine compound, and conforming to pharmacopoeial specifications formed from the said novel crystalline form of quinapril hydrochloride of formula (I). The crystalline quinapril hydrochloride is in the form nitroalkane solvate in which the nitroalkane is nitromethane, nitroethane and nitropropane. Each such nitroalkane solvate having particular characteristic X- ray diffraction patterns. A process for preparation of amorphous from of quinapril hydrochloride, substantially free of impurities, specially diketopiperazine compound, and conforming to pharmacopoeial specifications, using the novel crystalline quinapril hydrochloride as an intermediate. The process involves obtaining free base compound of formula (V) by adjusting the pH of a solution of the benzyl ester maleate salt of quinapril of formula (V) between 7.5-8.5 in a mixture of water and an organic solvent; catalytic hydrogenation of this compound (V) in an alcoholic solvent in the presence of concentrated hydrochloric acid or hydrogen chloride dissolved in an alcoholic solvent and in the presence of catalytic amounts of Pd/C to obtain a residue containing formula (I); crystallization of the said residue by evaporating the alcoholic solvent from a nitroalkane solvent to give crystalline quinapril hydrochloride, associated with a solvate of the nitroalkane solvent, and drying the crystalline quinapril hydrochloride nitroalkane solvate at a temperature between 40°C and 45°C under vacuum to give amorphous quinapril hydrochloride of formula (I).

  盐酸喹那普利的一种新颖结晶形式，其化学式为(I)。一种基本上无杂质的盐酸喹那普利无定形形式，特别是二酮哌嗪化合物，并且符合药典规格，由所述的盐酸喹那普利新颖结晶形式（化学式为I）形成。该结晶形式的盐酸喹那普利是以硝基烷为溶剂的溶剂化物，其中硝基烷是硝基甲烷、硝基乙烷和硝基丙烷。每一种这样的硝基烷溶剂化物都具有特定的特征X-射线衍射图谱。一种制备基本上无杂质，特别是二酮哌嗪化合物，并符合药典规格的盐酸喹那普利无定形形式的过程，使用新颖的结晶盐酸喹那普利作为中间体。该过程包括通过将喹那普利苯甲基酯马来酸盐（化学式为V）的水和有机溶剂混合溶液的pH值调整在7.5-8.5之间，获得自由碱化合物（化学式为V）；在醇溶剂中对该化合物（V）进行催化氢化，在浓盐酸或溶于醇溶剂中的氯化氢的存在下，以及在Pd/C的催化量存在下，获得含有化学式（I）的残留物；通过从硝基烷溶剂中蒸发醇溶剂使所述残留物结晶，得到与硝基烷溶剂的溶剂化物相关的结晶盐酸喹那普利，并在40°C至45°C的温度下，在真空下干燥结晶盐酸喹那普利硝基烷溶剂化物，得到无定形的盐酸喹那普利（化学式为I）。
• Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types
  作者：Sylvester Klutchko、C. John Blankley、Robert W. Fleming、Jack M. Hinkley、Ann E. Werner、Ivan Nordin、Ann Holmes、Milton L. Hoefle、David M. Cohen

  DOI：10.1021/jm00160a026

  日期：1986.10

  The synthesis and angiotensin converting enzyme (ACE) inhibiting activities of quinapril (CI-906, 22), its active diacid (CI-928, 33), and its dimethoxy analogue (CI-925, 25) are reported. These tetrahydro-3-isoquinolinecarboxylic acid derivatives possess equivalent in vitro potency and in vivo efficacy to enalapril. Sulfhydryl analogues with the same structural variation are also highly potent. In

  据报道奎纳普利（CI-906，22），其活性二酸（CI-928，33）和其二甲氧基类似物（CI-925，25）的合成和血管紧张素转化酶（ACE）抑制活性。这些四氢-3-异喹啉羧酸衍生物具有与依那普利相当的体外效能和体内功效。具有相同结构变化的巯基类似物也非常有效。相反，四氢-1-异喹啉羧酸和同源异吲哚啉-1-羧酸类似物在两种类型的效力上显示出惊人的差异，巯基类似物基本上是无活性的，而非巯基类似物与脯氨酸原型是等效的。这是第一个证据表明小分子ACE抑制剂的两个主要结构类别可能存在其他结合模式。
• X = Y - ZH systems as potential 1,3-dipoles. Part 40. Chiral azomethine ylides from homochiral cyclic α-amino esters. Unusual regiospecific deprotonation of iminium ions.
  作者：Ronald Grigg、Zoran Rankovic、Mark Thornton-Pett、Anoma Somasunderam

  DOI：10.1016/s0040-4020(01)96273-8

  日期：1993.9

  of iminium ions from cyclic secondary α-amino esters and bifunctional carbonyl compounds and their regiospecific or regioselective conversion to homochiral azomethine ylides. The endo-exo selectivity in the cycloadditions of these azomethine ylides is sensitive to the bifunctional carbonyl compound employed.

  甲1,3 -应变和电荷加速1,5-H位移在从环状仲α氨基酯和双官能的羰基化合物和它们的区域专一或区域选择性转化为纯手性甲亚胺叶立德立体有择形成亚胺离子的重要因素。这些偶氮甲亚胺基团的环加成中的内-外选择性对所用的双官能羰基化合物是敏感的。
• Studies on angiotensin converting enzyme inhibitors. III. 2-Carboxyethylcarbamoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives.
  作者：KIMIAKI HAYASHI、KENICHI NUNAMI、KAZUO SAKAI、YASUHIKO OZAKI、JYOJI KATO、KEIZO KINASHI、NAOTO YONEDA

  DOI：10.1248/cpb.33.2011

  日期：——

  (3S)-2-[N-Substituted N-(2-carboxyethyl) carbamoyl]-1, 2, 3, 4-tetrahydroisoquinoline-3-carboxylic acid derivaties (8a-d and 12a-t) and their monoester compounds (13a-k) were synthesized by condensation of (3S)-1, 2, 3, 4-tetrahydroisoquinoline-3-carboxylates (6a, b), 3-aminopropionates (5a, b or 10a-m) and phosgene, followed by deprotection of ester groups. Their in vitro angiotensin converting enzyme (ACE) inhibitory activities and antihypertensive effects were evaluated, and the structure-activity relationship is discussed. Some of the N-ethylcarbamoyl analogs (12h, 12j, 12k, 12l and 12o), which had hydrophobic substituents (C8H17-C12H25, CH2CH2Ph) at the α-position to the carboxyl group in the side chain, showed potent in vitro ACE inhibitory activities with IC50 values of 4.0-8.8×10-9M. The monoesters 13e, 13h, and 13i reduced the systolic blood pressure by more than 30 mmHg in spontaneously hypertensive rats (SHR) at an oral dose of 50mg/kg.

  (3S)-2-[N-取代的N-(2-羧乙基)氨基甲酸]-1, 2, 3, 4-四氢异喹啉-3-羧酸衍生物 (8a-d 和 12a-t) 及其单酯化合物 (13a-k) 通过 (3S)-1, 2, 3, 4-四氢异喹啉-3-羧酸酯 (6a, b)、3-氨基丙酸酯 (5a, b 或 10a-m) 和氯仿的缩合反应合成，随后去保护酯基。评估了它们在体外的血管紧张素转化酶 (ACE) 抑制活性及抗高血压效果，并讨论了结构-活性关系。一些具有疏水取代基（C8H17-C12H25，CH2CH2Ph）在侧链α位与羧基相邻的N-乙基氨基甲酸类似物 (12h, 12j, 12k, 12l 和 12o) 显示出强大的体外ACE抑制活性，IC50值为4.0-8.8×10^-9M。单酯化合物13e、13h和13i在口服剂量为50mg/kg时，能使自发性高血压大鼠 (SHR) 的收缩压下降超过30 mmHg。
• Studies on angiotensin-converting enzyme inhibitors. I. Syntheses and angiotensinconverting enzyme inhibitory activity of 2-(3-mercaptopropionyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives.
  作者：KIMIAKI HAYASHI、YASUHIKO OZAKI、KENICHI NUNAMI、TOMOFUMI UCHIDA、JYOJI KATO、KEIZO KINASHI、NAOTO YONEDA

  DOI：10.1248/cpb.31.570

  日期：——

  (3S)-2-[(2S)-3-Mercapto-2-methylpropionyl]-1, 2, 3, 4-tetrahydroisoquinoline-3-carboxylic acid [(3S), (2S)-6a] was prepared by the reaction of (3S)-1, 2, 3, 4-tetrahydroisoquinoline-3-carboxylic acid tert-butyl ester [(3S)-2a] or benzyl ester [(3S)-2b] with 3-benzoylthio-2-methylpropionyl chloride (3a), followed by fractional crystallization and removal of the protective group. The absolute configuration of (3S), (2S)-6a was confirmed by X-ray diffraction analysis of the thiazepino [4, 3-b] isoquinoline compound (7) derived from 6a. Resolution of 3-benzoylthio-2-methylpropionic acid (8) was completed by using optically active phenylalanine amide as a resolving agent. The other optical isomers of (3S), (2S)-6a were prepared by the reaction of (3S)- or (3R)-2b with optically active 3a. The in vitro ACE inhibitory activity of each isomer of 6a was evaluated. Among them, (3S), (2S)-6a was found to be the most potent inhibitor with an IC50 value of 8.6×10-9M. Compound (3S), (2S)-6a induced a dose-dependent inhibition of the pressor response to angiotensin I after oral administration to normotensive anesthetized rats. Moreover, (3S), (2S)-6a markedly reduced the systolic blood pressure in renal hypertensive rats (RHR) and spontaneously hypertensive rats (SHR). The in vivo ACE inhibitory activity and the hypotensive effects of (3S), (2S)-6a were comparable to those of captopril.

  (3S)-2-[(2S)-3-巯基-2-甲基丙酰基]-1, 2, 3, 4-四氢异喹啉-3-羧酸[(3S), (2S)-6a]是通过(3S)-1, 2, 3, 4-四氢异喹啉-3-羧酸叔丁基酯[(3S)-2a]或苄基酯[(3S)-2b]与3-苯甲酰硫-2-甲基丙酰氯(3a)反应制备而成，随后通过分馏结晶去除保护基团。通过对由6a衍生的噻唑烯[4, 3-b]异喹啉化合物(7)进行X射线衍射分析，确认了(3S), (2S)-6a的绝对构型。使用光学活性的苯丙氨酸酰胺作为分解剂完成了3-苯甲酰硫-2-甲基丙酸(8)的分解。通过(3S)-或(3R)-2b与光学活性3a反应制备了(3S), (2S)-6a的其他光学异构体。评估了每种6a异构体的体外ACE抑制活性。其中，(3S), (2S)-6a被发现是最有效的抑制剂，IC50值为8.6×10^-9M。化合物(3S), (2S)-6a在该显混合型麻醉大鼠口服给药后，诱导了对血管紧张素I的加压反应的剂量依赖性抑制。此外，(3S), (2S)-6a显著降低了肾性高血压大鼠(RHR)和自发性高血压大鼠(SHR)的收缩压。(3S), (2S)-6a的体内ACE抑制活性和降压效果与卡托普利相当。